Paratek announced the launch of Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). It is the first once-daily antibiotic approved to treat CABP and ABSSSI that is available in both an intravenous (IV) and oral formulation.
Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains. Specifically, it is indicated for CABP caused by Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae and ABSSSI caused by S. aureus (methicillin-susceptible and -resistant isolates), S. lugdunensis, S. pyogenes, S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and K. pneumoniae.
Concurrently, Paratek announced the availability of 3 FDA-approved antimicrobial susceptibility tests (Hardy Diagnostics’ Omadacycline Susceptibility Disk [HardyDisk], Liofilchem Omadacycline MIC Test Strip, and Thermo Scientific Sensititre MIC Plate) to help guide clinicians toward the appropriate use of Nuzyra, and the KEYSTONE Surveillance Program, which provides access to current antimicrobial surveillance susceptibility data.
Nuzyra is available as 150mg strength tablets in 6-, 14-, and 16-count blisters, and as a 100mg lyophilized powder for IV infusion (after reconstitution and dilution) in single-dose vials.
For more information call (833) 727-2835 or visit Nuzyra.com.
This article originally appeared on MPR